Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team
October 09 2017 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced the
appointment of 11 employees to its Research and Development team
located in Durham, NC. The new employees will initially focus on
preclinical activities associated with the drug delivery asset
acquisition from Envisia Therapeutics announced on October 5,
2017.
In connection with the acceptance of their positions, the 11
individuals on a combined basis will receive awards totaling 83,700
stock options. The stock options will vest over 4 years, with 25%
vesting on the first anniversary of the hire date and the remainder
vesting ratably on each of the subsequent 36 monthly anniversaries
of the hire date. These awards were made outside of Aerie’s
stockholder-approved equity incentive plan and were approved by the
Company’s Compensation Committee as an inducement material to the
11 individuals entering into employment with the Company in
reliance on NASDAQ Listing Rule 5635(c)(4), which requires this
public announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two current product candidates are
once-daily intraocular pressure lowering therapies with novel
mechanisms of action to treat patients with glaucoma or ocular
hypertension. The NDA (new drug application) for RhopressaTM
(netarsudil ophthalmic solution) 0.02% was submitted to the U.S.
Food and Drug Administration (FDA) in February 2017, and, in May
2017, the FDA set the PDUFA (Prescription Drug User Fee Act) goal
date for the completion of the FDA’s review of the RhopressaTM NDA
for February 28, 2018. Aerie’s second product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is
a fixed dose combination of RhopressaTM and widely prescribed PGA
latanoprost, achieved its primary efficacy endpoint in two Phase 3
registration trials, named Mercury 1 and Mercury 2, and also
achieved successful 12-month safety and efficacy results in Mercury
1. The RoclatanTM NDA submission is expected to take place in the
first half of 2018. Aerie is also focused on international
expansion and the development of additional product candidates and
technologies in ophthalmology.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the success, timing
and cost of our ongoing and anticipated preclinical studies and
clinical trials for our current product candidates, including
statements regarding the timing of initiation and completion of the
studies and trials; our expectations regarding the clinical
effectiveness of our product candidates and results of our clinical
trials; the timing of and our ability to request, obtain and
maintain FDA or other regulatory authority approval of, or other
action with respect to, our product candidates, including the
expected timing of, and timing of regulatory and/or other review
of, filings for our product candidates; our expectations regarding
the commercialization of our product candidates; the potential
advantages of our product candidates; our plans to pursue
development of our product candidates for additional indications
and other therapeutic opportunities; our plans to explore possible
uses of our existing proprietary compounds beyond glaucoma; our
ability to protect our proprietary technology and enforce our
intellectual property rights; and our expectations regarding
strategic operations, including our ability to in-license, acquire
and develop additional ophthalmic products or product candidates or
technologies. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). In particular, the receipt of the
PDUFA goal date notification does not constitute FDA approval of
the RhopressaTM NDA, and there can be no assurance that the FDA
will complete its review by the PDUFA goal date, that the FDA will
not require changes or additional data, whether as a result of
recommendations, if any, made by any FDA advisory committee or
otherwise, that must be made or received before it will approve the
NDA, if ever, or that the FDA will approve the NDA. Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171009005171/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsInvestorsAmi Bavishi,
212-213-0006abavishi@burnsmc.comorMediaJustin Jackson,
212-213-0006jjackson@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024